,address1,city,zip,country,phone,fax,website,industry,sector,longBusinessSummary,fullTimeEmployees,companyOfficers,auditRisk,boardRisk,compensationRisk,shareHolderRightsRisk,overallRisk,governanceEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,exDividendDate,payoutRatio,beta,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,priceToSalesTrailing12Months,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,heldPercentInsiders,heldPercentInstitutions,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,enterpriseToRevenue,enterpriseToEbitda,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,targetHighPrice,targetLowPrice,targetMeanPrice,targetMedianPrice,recommendationMean,recommendationKey,numberOfAnalystOpinions,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,totalRevenue,debtToEquity,revenuePerShare,returnOnAssets,returnOnEquity,grossProfits,freeCashflow,operatingCashflow,revenueGrowth,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,Hoffsveien 4,Oslo,0275,Norway,47 22 06 22 10,47 22 06 22 18,https://www.photocure.com,Drug Manufacturers—Specialty & Generic,Healthcare,"Photocure ASA, a specialty pharmaceutical company, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products in Nordic countries, Germany, France, Austria, the United Kingdom, the BeNeLux, Italy, other European Countries, Canada, and the United States. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It also develops Cevira for the treatment of human papilloma virus infection and precancerous lesions of the cervix. The company sells its products to pharmaceutical wholesalers, pharmacies, and hospitals through license partners. Photocure ASA was founded in 1993 and is headquartered in Oslo, Norway.",87,"{'maxAge': 1, 'name': 'Mr. Daniel  Schneider', 'title': 'Pres & CEO', 'exercisedValue': 0, 'unexercisedValue': 0}",1,3,7,1,4,1693526400,86400,2,44.05,44.4,43.4,44.7,44.05,44.4,43.4,44.7,1369267200,0.0,0.890015,90.833336,27686,27686,80886,64543,64543,43.5,43.8,140900,97900,1181808512,40.7,115.0,2.5606322,45.21,69.568,0.0,0.0,NOK,949563456,-0.08415,22903502,27105700,0.00716,0.50639,17.249,2.5276825,1672444800,1703980800,1688083200,-38837000,-1.42,0.48,2.057,2689.981,OSL,EQUITY,PHO.OL,PHO.OL,PHOTOCURE,Photocure ASA,959670000,Europe/Oslo,CEST,7200000,43.6,140.0,80.0,106.67,100.0,1.7,buy,3,258944992,9.553,353000,26700000,4.311,4.691,461529984,5.711,17.026,-0.0133299995,-0.08243,370435000,23210624,42065000,0.435,0.94632006,0.00075999997,-0.03328,NOK,
1,Hoffsveien 4,Oslo,0275,Norway,47 22 06 22 10,47 22 06 22 18,https://www.photocure.com,Drug Manufacturers—Specialty & Generic,Healthcare,"Photocure ASA, a specialty pharmaceutical company, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products in Nordic countries, Germany, France, Austria, the United Kingdom, the BeNeLux, Italy, other European Countries, Canada, and the United States. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It also develops Cevira for the treatment of human papilloma virus infection and precancerous lesions of the cervix. The company sells its products to pharmaceutical wholesalers, pharmacies, and hospitals through license partners. Photocure ASA was founded in 1993 and is headquartered in Oslo, Norway.",87,"{'maxAge': 1, 'name': 'Mr. Erik  Dahl', 'age': 65, 'title': 'Chief Financial Officer', 'yearBorn': 1957, 'exercisedValue': 0, 'unexercisedValue': 0}",1,3,7,1,4,1693526400,86400,2,44.05,44.4,43.4,44.7,44.05,44.4,43.4,44.7,1369267200,0.0,0.890015,90.833336,27686,27686,80886,64543,64543,43.5,43.8,140900,97900,1181808512,40.7,115.0,2.5606322,45.21,69.568,0.0,0.0,NOK,949563456,-0.08415,22903502,27105700,0.00716,0.50639,17.249,2.5276825,1672444800,1703980800,1688083200,-38837000,-1.42,0.48,2.057,2689.981,OSL,EQUITY,PHO.OL,PHO.OL,PHOTOCURE,Photocure ASA,959670000,Europe/Oslo,CEST,7200000,43.6,140.0,80.0,106.67,100.0,1.7,buy,3,258944992,9.553,353000,26700000,4.311,4.691,461529984,5.711,17.026,-0.0133299995,-0.08243,370435000,23210624,42065000,0.435,0.94632006,0.00075999997,-0.03328,NOK,
2,Hoffsveien 4,Oslo,0275,Norway,47 22 06 22 10,47 22 06 22 18,https://www.photocure.com,Drug Manufacturers—Specialty & Generic,Healthcare,"Photocure ASA, a specialty pharmaceutical company, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products in Nordic countries, Germany, France, Austria, the United Kingdom, the BeNeLux, Italy, other European Countries, Canada, and the United States. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It also develops Cevira for the treatment of human papilloma virus infection and precancerous lesions of the cervix. The company sells its products to pharmaceutical wholesalers, pharmacies, and hospitals through license partners. Photocure ASA was founded in 1993 and is headquartered in Oslo, Norway.",87,"{'maxAge': 1, 'name': 'Mr. David  Moskowitz', 'title': 'Head of Investor Relations', 'exercisedValue': 0, 'unexercisedValue': 0}",1,3,7,1,4,1693526400,86400,2,44.05,44.4,43.4,44.7,44.05,44.4,43.4,44.7,1369267200,0.0,0.890015,90.833336,27686,27686,80886,64543,64543,43.5,43.8,140900,97900,1181808512,40.7,115.0,2.5606322,45.21,69.568,0.0,0.0,NOK,949563456,-0.08415,22903502,27105700,0.00716,0.50639,17.249,2.5276825,1672444800,1703980800,1688083200,-38837000,-1.42,0.48,2.057,2689.981,OSL,EQUITY,PHO.OL,PHO.OL,PHOTOCURE,Photocure ASA,959670000,Europe/Oslo,CEST,7200000,43.6,140.0,80.0,106.67,100.0,1.7,buy,3,258944992,9.553,353000,26700000,4.311,4.691,461529984,5.711,17.026,-0.0133299995,-0.08243,370435000,23210624,42065000,0.435,0.94632006,0.00075999997,-0.03328,NOK,
3,Hoffsveien 4,Oslo,0275,Norway,47 22 06 22 10,47 22 06 22 18,https://www.photocure.com,Drug Manufacturers—Specialty & Generic,Healthcare,"Photocure ASA, a specialty pharmaceutical company, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products in Nordic countries, Germany, France, Austria, the United Kingdom, the BeNeLux, Italy, other European Countries, Canada, and the United States. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It also develops Cevira for the treatment of human papilloma virus infection and precancerous lesions of the cervix. The company sells its products to pharmaceutical wholesalers, pharmacies, and hospitals through license partners. Photocure ASA was founded in 1993 and is headquartered in Oslo, Norway.",87,"{'maxAge': 1, 'name': 'Dr. Anders  Neijber M.D.', 'title': 'Chief Medical Officer of Global Medical Affairs, Clinical Devel. and R&D', 'exercisedValue': 0, 'unexercisedValue': 0}",1,3,7,1,4,1693526400,86400,2,44.05,44.4,43.4,44.7,44.05,44.4,43.4,44.7,1369267200,0.0,0.890015,90.833336,27686,27686,80886,64543,64543,43.5,43.8,140900,97900,1181808512,40.7,115.0,2.5606322,45.21,69.568,0.0,0.0,NOK,949563456,-0.08415,22903502,27105700,0.00716,0.50639,17.249,2.5276825,1672444800,1703980800,1688083200,-38837000,-1.42,0.48,2.057,2689.981,OSL,EQUITY,PHO.OL,PHO.OL,PHOTOCURE,Photocure ASA,959670000,Europe/Oslo,CEST,7200000,43.6,140.0,80.0,106.67,100.0,1.7,buy,3,258944992,9.553,353000,26700000,4.311,4.691,461529984,5.711,17.026,-0.0133299995,-0.08243,370435000,23210624,42065000,0.435,0.94632006,0.00075999997,-0.03328,NOK,
4,Hoffsveien 4,Oslo,0275,Norway,47 22 06 22 10,47 22 06 22 18,https://www.photocure.com,Drug Manufacturers—Specialty & Generic,Healthcare,"Photocure ASA, a specialty pharmaceutical company, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products in Nordic countries, Germany, France, Austria, the United Kingdom, the BeNeLux, Italy, other European Countries, Canada, and the United States. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It also develops Cevira for the treatment of human papilloma virus infection and precancerous lesions of the cervix. The company sells its products to pharmaceutical wholesalers, pharmacies, and hospitals through license partners. Photocure ASA was founded in 1993 and is headquartered in Oslo, Norway.",87,"{'maxAge': 1, 'name': 'Mr. Tolv  Hillestad', 'title': 'Group Controller', 'exercisedValue': 0, 'unexercisedValue': 0}",1,3,7,1,4,1693526400,86400,2,44.05,44.4,43.4,44.7,44.05,44.4,43.4,44.7,1369267200,0.0,0.890015,90.833336,27686,27686,80886,64543,64543,43.5,43.8,140900,97900,1181808512,40.7,115.0,2.5606322,45.21,69.568,0.0,0.0,NOK,949563456,-0.08415,22903502,27105700,0.00716,0.50639,17.249,2.5276825,1672444800,1703980800,1688083200,-38837000,-1.42,0.48,2.057,2689.981,OSL,EQUITY,PHO.OL,PHO.OL,PHOTOCURE,Photocure ASA,959670000,Europe/Oslo,CEST,7200000,43.6,140.0,80.0,106.67,100.0,1.7,buy,3,258944992,9.553,353000,26700000,4.311,4.691,461529984,5.711,17.026,-0.0133299995,-0.08243,370435000,23210624,42065000,0.435,0.94632006,0.00075999997,-0.03328,NOK,
